We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+3.91%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$245M
AUM Growth
+$31M
Cap. Flow
+$33M
Cap. Flow %
13.48%
Top 10 Hldgs %
7.31%
Holding
511
New
57
Increased
251
Reduced
151
Closed
49

Top Buys

Rank Stock Value
1
JNK icon
State Street SPDR Bloomberg High Yield Bond ETF
JNK
+$1.9M
2
COIN icon
Coinbase
COIN
+$1.35M
3
DOCU
DocuSign
DOCU
+$1.32M
4
SPOT icon
Spotify
SPOT
+$1.28M
5
UAL icon
United Airlines
UAL
+$1.28M

Top Sells

Rank Stock Value
1
APP icon
Applovin
APP
+$1.14M
2
EXPE icon
Expedia Group
EXPE
+$1.04M
3
KKR icon
KKR & Co
KKR
+$976K
4
CME icon
CME Group
CME
+$974K
5
CPAY icon
Corpay
CPAY
+$948K

Sector Composition

Rank Sector Weight
1 Financials 29.48%
2 Technology 14.86%
3 Healthcare 14.81%
4 Industrials 11.61%
5 Consumer Discretionary 6.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
401
Edgewise Therapeutics
EWTX
$4.34B
$67.4K 0.03%
2,526
-2,619
-51% -$83.4K
MREO
402
Mereo BioPharma
MREO
$49.4M
$66.7K 0.03%
+19,060
New +$74.9K
EYPT icon
403
EyePoint Inc
EYPT
$1B
$66.7K 0.03%
+8,953
New +$83.3K
LENZ
404
LENZ Therapeutics
LENZ
$184M
$66.7K 0.03%
+2,309
New +$70.4K
VERA icon
405
Vera Therapeutics
VERA
$2.39B
$66.6K 0.03%
1,576
-889
-36% -$39.4K
CYTK icon
406
Cytokinetics
CYTK
$10.8B
$66.6K 0.03%
1,415
-332
-19% -$17.2K
COGT icon
407
Cogent Biosciences
COGT
$6.95B
$66.5K 0.03%
8,524
-1,742
-17% -$17.4K
RAPP
408
Rapport Therapeutics
RAPP
$2.01B
$66.3K 0.03%
+3,740
New +$82.9K
PCVX icon
409
Vaxcyte
PCVX
$7.88B
$66.2K 0.03%
809
-435
-35% -$43.2K
BHVN icon
410
Biohaven
BHVN
$2.07B
$66.1K 0.03%
1,770
-990
-36% -$46.2K
XNCR icon
411
Xencor
XNCR
$1.48B
$66K 0.03%
2,871
-1,452
-34% -$33.4K
DNTH icon
412
Dianthus Therapeutics
DNTH
$5.55B
$65.9K 0.03%
3,025
-397
-12% -$10.2K
DYN icon
413
Dyne Therapeutics
DYN
$4.28B
$65.4K 0.03%
2,776
+40
+1% +$1.18K
CRNX icon
414
Crinetics Pharmaceuticals
CRNX
$8.88B
$65.4K 0.03%
1,279
-683
-35% -$38.2K
CATX icon
415
Perspective Therapeutics
CATX
$327M
$65.4K 0.03%
20,487
+12,542
+158% +$102K
ACLX
416
DELISTED
Arcellx
ACLX
$65.3K 0.03%
852
-799
-48% -$69K
ABUS icon
417
Arbutus Biopharma
ABUS
$871M
$65.3K 0.03%
19,970
-9,192
-32% -$33.8K
SVRA icon
418
Savara
SVRA
$1.09B
$65.2K 0.03%
21,222
-1,479
-7% -$5.16K
NRIX icon
419
Nurix Therapeutics
NRIX
$2.51B
$65.1K 0.03%
3,458
-2,054
-37% -$47.1K
TYRA icon
420
Tyra Biosciences
TYRA
$1.84B
$65.1K 0.03%
4,686
+44
+0.9% +$799
THRD
421
DELISTED
Third Harmonic Bio
THRD
$65K 0.03%
+6,320
New +$78.7K
ATXS
422
DELISTED
Astria Therapeutics
ATXS
$64.8K 0.03%
+7,247
New +$77K
VERV
423
DELISTED
Verve Therapeutics
VERV
$64.4K 0.03%
11,411
-5,044
-31% -$28.4K
NUVL
424
DELISTED
Nuvalent
NUVL
$64.1K 0.03%
819
-346
-30% -$32.3K
TRML
425
DELISTED
Tourmaline Bio
TRML
$64K 0.03%
+3,157
New +$79.5K
15 16
17
18 19

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
RC
Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Virtus ETF Advisers's Q4 2024 Portfolio in Review

As of Q4 2024, Virtus ETF Advisers held 511 positions worth $245M, up 15% from $214M the previous quarter. Its ten largest holdings account for 7.3% of the portfolio.

Virtus ETF Advisers deployed $33M of net new capital in Q4 2024, opening 57 new positions and adding to 251 existing holdings. Its largest new stake was State Street SPDR Bloomberg High Yield Bond ETF: 19,660 shares worth $1.88M.

By sector, the portfolio is most concentrated in Financials at 29% of assets, up from 28% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was Applovin, an estimated $1.14M trimmed.

  • Virtus ETF Advisers's largest Q4 2024 buy was State Street SPDR Bloomberg High Yield Bond ETF: 19,660 shares worth $1.88M.
  • Virtus ETF Advisers added most to Eagle Point Credit Company in Q4 2024, an estimated $515K increase.
  • Virtus ETF Advisers's biggest Q4 2024 reduction was Applovin, cutting an estimated $1.14M.
  • Virtus ETF Advisers fully exited Expedia Group in Q4 2024, selling an estimated $1.04M.
  • Virtus ETF Advisers's ten largest holdings make up 7.3% of its $245M portfolio in Q4 2024.
  • Virtus ETF Advisers opened 57 new positions and closed 49 in Q4 2024.
  • Virtus ETF Advisers's portfolio value rose 15% quarter-over-quarter to $245M.

Based on Virtus ETF Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.